Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Prostate cancer cells exhibit altered cellular metabolism but, notably, not the hallmarks of Warburg metabolism. Prostate cancer cells exhibit increased synthesis of fatty acids (FA); however, little is known about how extracellular FAs, such as those in the circulation, may support prostate cancer progression. Here, we show that increasing FA availability increased intracellular triacylglycerol content in cultured patient-derived tumor explants, LNCaP and C4-2B spheroids, a range of prostate cancer cells (LNCaP, C4-2B, 22Rv1, PC-3), and prostate epithelial cells (PNT1). Extracellular FAs are the major source (∼83%) of carbons to the total lipid pool in all cell lines, compared with glucose (∼13%) and glutamine (∼4%), and FA oxidation rates are greater in prostate cancer cells compared with PNT1 cells, which preferentially partitioned extracellular FAs into triacylglycerols. Because of the higher rates of FA oxidation in C4-2B cells, cells remained viable when challenged by the addition of palmitate to culture media and inhibition of mitochondrial FA oxidation sensitized C4-2B cells to palmitate-induced apoptosis. Whereas in PC-3 cells, palmitate induced apoptosis, which was prevented by pretreatment of PC-3 cells with FAs, and this protective effect required DGAT-1-mediated triacylglycerol synthesis. These outcomes highlight for the first-time heterogeneity of lipid metabolism in prostate cancer cells and the potential influence that obesity-associated dyslipidemia or host circulating has on prostate cancer progression. IMPLICATIONS: Extracellular-derived FAs are primary building blocks for complex lipids and heterogeneity in FA metabolism exists in prostate cancer that can influence tumor cell behavior.

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-18-0347DOI Listing

Publication Analysis

Top Keywords

prostate cancer
36
cancer cells
20
cells
12
extracellular fas
12
prostate
10
cancer
9
fatty acids
8
cells exhibit
8
metabolism prostate
8
cancer progression
8

Similar Publications

Purpose: To evaluate a generative artificial intelligence (GAI) framework for creating readable lay abstracts and summaries (LASs) of urologic oncology research, while maintaining accuracy, completeness, and clarity, for the purpose of assessing their comprehension and perception among patients and caregivers.

Methods: Forty original abstracts (OAs) on prostate, bladder, kidney, and testis cancers from leading journals were selected. LASs were generated using a free GAI tool, with three versions per abstract for consistency.

View Article and Find Full Text PDF

Super Responder of 177Lu-PSMA-617 PSMA Therapy in Patient With End-Stage Renal Disease on Hemodialysis.

Clin Nucl Med

September 2025

Department of Radiology and Nuclear Medicine, Comprehensive Cancer Care and Research Center (SQCCCRC), University Medical City, Muscat, Oman.

PSMA-targeted radioligand therapies with 177Lu-PSMA-617 have shown promising response rates with favorable toxicity in patients with metastasized castration-resistant prostate cancer. We report a case of a 72-year-old man with metastatic castration-resistant prostate cancer having comorbidities of DM, HTN, and end-stage renal disease (ESRD) on regular hemodialysis. The patient received 2 doses of 7.

View Article and Find Full Text PDF

Discovery of -(thiazol-2-yl) Furanamide Derivatives as Potent Orally Efficacious AR Antagonists with Low BBB Permeability.

J Med Chem

September 2025

State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China.

Resistance-conferring mutations in the androgen receptor (AR) ligand-binding pocket (LBP) compromise the effectiveness of clinically approved orthosteric AR antagonists. Targeting the dimerization interface pocket (DIP) of AR presents a promising therapeutic approach. In this study, we report the design and optimization of -(thiazol-2-yl) furanamide derivatives as novel AR DIP antagonists, among which was the most promising candidate.

View Article and Find Full Text PDF

Importance: Multiparametric magnetic resonance imaging (MRI), with or without prostate biopsy, has become the standard of care for diagnosing clinically significant prostate cancer. Resource capacity limits widespread adoption. Biparametric MRI, which omits the gadolinium contrast sequence, is a shorter and cheaper alternative offering time-saving capacity gains for health systems globally.

View Article and Find Full Text PDF